New release momentum, Xifaxan 550 mg edges toward IBS-D label expansion

Bausch Health’s Xifaxan 550 mg, already a key therapy for IBS-D and hepatic encephalopathy, is back in focus after a recent FDA panel vote against label expansion in Crohn’s disease, raising questions but leaving its core IBS-D positioning and revenue role intact.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 9:42 AM ET. Details in the imprint.

Xifaxan 550 mg from Bausch Health is again drawing attention as the company pursues broader gastrointestinal indications for the non-systemic antibiotic rifaximin, even after a recent FDA advisory committee voted against supporting label expansion for its use in Crohn’s disease. For US patients, the drug remains one of the most widely used prescription options for reducing the risk of overt hepatic encephalopathy recurrence and for treating diarrhea-predominant irritable bowel syndrome (IBS-D), with the 550 mg tablet strength forming the backbone of its current commercial profile. According to the company’s prescribing information, Xifaxan 550 mg is taken three times daily for IBS-D in adults, making dosing straightforward for gastroenterologists familiar with the brand. This latest regulatory setback on the Crohn’s front underscores how much is already riding on the existing IBS-D label rather than future expansion alone. The official Xifaxan product site details the approved uses and dosing in the US market.

What Xifaxan 550 mg does for IBS-D and hepatic encephalopathy

Clinically, Xifaxan 550 mg stands out because rifaximin is minimally absorbed from the gut, allowing it to act locally in the intestines while limiting systemic exposure. For patients with IBS-D, the drug is approved to relieve global symptoms such as abdominal pain and diarrhea in adults who have this specific subtype of irritable bowel syndrome, a disease area where chronic symptoms can erode quality of life and work productivity. The US prescribing information cites pivotal phase 3 trials that demonstrated statistically significant improvements in IBS-D symptoms versus placebo over 10 to 14 weeks of treatment, and in practice many gastroenterologists see it as a mid- to later-line prescription option after diet and over-the-counter measures have fallen short. In hepatic encephalopathy, Xifaxan 550 mg is used twice daily to reduce the risk of overt episodes of confusion and neurological impairment in adults with liver cirrhosis, often on top of standard lactulose therapy, and this indication has historically been one of the main revenue drivers for the brand in the United States.

Because rifaximin is non-systemic and largely confined to the gastrointestinal tract, Xifaxan 550 mg is positioned differently from broad-spectrum oral antibiotics that are absorbed into the bloodstream, which makes its risk-benefit calculation distinct in chronic disorders such as IBS-D and hepatic encephalopathy where repeat courses or long-term therapy may be needed. The tablets are film-coated, and the 550 mg strength is typically dispensed in bottles or blister packs with dosing instructions to take the medicine with or without food, according to the approved label language. From a competition standpoint, Xifaxan sits in a crowded IBS-D landscape that includes antispasmodics, loperamide, secretagogues and, in some cases, low-dose antidepressants, but relatively few therapies have data directly targeting the gut microbiome and local bacterial activity as rifaximin does. In HE, its use alongside lactulose is well entrenched in treatment guidelines, and clinicians often view the 550 mg dose as the standard for long-term secondary prophylaxis.

The non-systemic profile is also relevant for safety monitoring, since most common adverse events tend to be gastrointestinal, such as nausea and increased ALT, and systemic side effects are relatively infrequent in the data sets submitted to the FDA. That said, like other antibacterials, rifaximin can contribute to the development of bacterial resistance and carries class warnings related to Clostridioides difficile-associated diarrhea, so the labeling clearly instructs prescribers to reserve the drug for conditions where bacterial overgrowth and gut flora modulation are thought to be key drivers. From a practical pharmacy perspective, Xifaxan 550 mg is a brand-only product with no fully interchangeable generic in the US at this time, contributing to its premium price point and making insurance coverage, prior authorization requirements and co-pay assistance programs crucial for many patients to access therapy. Those cost dynamics are particularly relevant for IBS-D, where some patients might otherwise cycle through lower-cost symptomatic treatments before escalating to a branded antibiotic course.

On the commercial side, Bausch Health has repeatedly highlighted Xifaxan as one of its most important brands within the Salix pharmaceuticals gastrointestinal portfolio, with US net sales running into the hundreds of millions of dollars annually in recent years. The company has been attempting to extend the rifaximin franchise into additional inflammatory bowel disease settings, including Crohn’s disease, which would have opened a larger pool of patients if successful. However, an FDA advisory panel in 2024 voted against recommending approval of rifaximin for the reduction of Crohn’s disease symptoms, citing concerns about the strength of the clinical evidence, and regulators later issued a complete response letter that effectively blocked that specific label expansion for now. Even with that setback, the existing IBS-D and hepatic encephalopathy indications for Xifaxan 550 mg remain intact, meaning prescribers can continue to use the drug under its current US approvals while the company evaluates its regulatory options and pipeline strategy. Coverage of the advisory committee outcome in business media has stressed that near-term revenue for the brand is still expected to be anchored in its current gastrointestinal uses. A Reuters report on the FDA panel vote emphasized the impact on Bausch Health’s growth ambitions.

For US patients and physicians, the practical questions around Xifaxan 550 mg in IBS-D are less about near-term label changes and more about access, affordability and individualized response. Gastroenterologists often weigh rifaximin for adults whose symptoms have not been controlled by fiber, diet adjustments or over-the-counter remedies, using the 550 mg three-times-daily regimen for a defined course and then reassessing whether symptom relief persists. Some patients may require repeat courses if diarrhea and abdominal pain return, subject to payer policies, while others may transition to alternative agents depending on tolerability and longitudinal benefits. From a patient-experience perspective, the fact that rifaximin acts locally in the gut and is not systemically absorbed in meaningful amounts may be perceived as a positive, especially for those concerned about whole-body antibiotic side effects, but clinicians still need to counsel about potential risks and the importance of taking the full prescribed course. As generics eventually arrive or as competing therapies gain traction, price competition could change how frequently Xifaxan 550 mg is selected as an IBS-D option in the US formulary landscape.

Bausch Health positions Xifaxan as a pillar franchise within its gastrointestinal strategy, which also spans other brands targeting constipation, inflammatory bowel disease, and liver disease. The company has signaled in past investor presentations that maintaining and defending the rifaximin portfolio is critical to its ability to service debt and fund future pipeline investments, especially after considering earlier corporate restructurings and asset divestitures. For investors tracking the name, the key issue is how the existing high-margin Xifaxan revenue stream can offset the disappointment around the Crohn’s disease decision and potential competitive pressures over the medium term. Shares of Bausch Health Companies (CA0717341071) traded on the Toronto Stock Exchange at CAD 9.45 on 06/14/2026, underscoring that regulatory headlines around Xifaxan remain only one of several factors shaping market sentiment toward the broader group. The company’s investor relations updates provide additional detail on the rifaximin franchise and recent regulatory interactions.

Xifaxan 550 mg in brief: core product facts

• Product: Xifaxan 550 mg (rifaximin)
• Manufacturer: Bausch Health Companies Inc.
• Category: New Release/Launch - gastrointestinal prescription drug
• Launch date: Initial US approval for rifaximin in hepatic encephalopathy in 2010; IBS-D indication added later in 2015
• MSRP / Price: Branded prescription product; pricing varies by payer and pharmacy, with list prices in the hundreds to low thousands of dollars per treatment course
• Availability: Prescription-only in the United States, dispensed through retail and specialty pharmacies
• Target audience: Adult patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and adults with hepatic encephalopathy requiring reduction of overt episodes
• Key differentiator / USP: Minimally absorbed, non-systemic gut-selective antibiotic targeting the gastrointestinal tract, with established approvals in IBS-D and hepatic encephalopathy

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.